Crystagen vs Thymosin Alpha-1
A side-by-side research comparison of Crystagen and Thymosin Alpha-1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Crystagen | Thymosin Alpha-1 |
|---|---|---|
| Full name | Crystagen (Immune Peptide Bioregulator) | Thymosin Alpha-1 (Thymalfasin) |
| Category | Immune Support | Immune Support |
| Status | Research compound (peptide bioregulator) | Approved internationally (not FDA-approved) |
| Mechanism | As a signal peptide, it is proposed to enter cells and regulate gene expression in immune tissue, supporting normal thymic and lymphoid function, immune cell maturation, and balanced immune responses. | Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles. |
| Molecular weight | ~ (short peptide) | 3108.3 Da |
| Half-life | Short (peptide) | ~2-3 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~85% subcutaneous |
| Typical dose | ~1-2 capsules/day or short injectable courses | 1.6-3.2 mg |
| Frequency | Once daily | 2-3x per week |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Crystagen reported benefits
- Immune regulation support
- Thymic/lymphoid tissue support (proposed)
- Immune resilience
- Short course-based protocol
- Part of bioregulator longevity systems
Thymosin Alpha-1 reported benefits
- Enhanced T-cell immunity
- Anti-viral activity
- Dendritic cell activation
- Cancer immunosurveillance
- Vaccine adjuvant effects
Related comparisons
Research and educational reference only. Not medical advice.